Pfiz­er on­col­o­gy R&D ex­ec heads to Aduro as new CMO; Army dumps Tonix re­search con­tract

→ A trou­bled Aduro has re­cruit­ed a Pfiz­er can­cer R&D ex­ec to take the chief med­ical of­fi­cer’s job. Dim­it­ry S.A. Nuyten is mov­ing from his job as Vice Pres­i­dent and Im­muno-On­col­o­gy Clin­i­cal De­vel­op­ment Leader to the biotech. His stint at Pfiz­er put Nuyten in charge of its Baven­cio work, part­nered with Mer­ck KGaA. “We are ex­treme­ly pleased to wel­come Dim­it­ry as we pre­pare to broad­en our de­vel­op­ment plans for STING ag­o­nist ADU-S100 and ini­ti­ate our first in hu­man study of an­ti-APRIL an­ti­body BION-1301 in IgA nephropa­thy,” not­ed CEO Stephen T. Isaacs in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER